Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22


Effect of copayment policies on initial medication non-adherence according to income: a population-based study.

Aznar-Lou I, Pottegård A, Fernández A, Peñarrubia-María MT, Serrano-Blanco A, Sabés-Figuera R, Gil-Girbau M, Fajó-Pascual M, Moreno-Peral P, Rubio-Valera M.

BMJ Qual Saf. 2018 Mar 15. pii: bmjqs-2017-007416. doi: 10.1136/bmjqs-2017-007416. [Epub ahead of print]


Psychometric Properties of the Cognitive Emotion Regulation Questionnaire (CERQ) in Patients with Fibromyalgia Syndrome.

Feliu-Soler A, Reche-Camba E, Borràs X, Pérez-Aranda A, Andrés-Rodríguez L, Peñarrubia-María MT, Navarro-Gil M, García-Campayo J, Bellón JA, Luciano JV.

Front Psychol. 2017 Dec 13;8:2075. doi: 10.3389/fpsyg.2017.02075. eCollection 2017.


Impact of initial medication non-adherence to SSRIs on medical visits and sick leaves.

Aznar-Lou I, Iglesias-González M, Gil-Girbau M, Serrano-Blanco A, Fernández A, Peñarrubia-María MT, Sabés-Figuera R, Murrugarra-Centurión AG, March-Pujol M, Bolívar-Prados M, Rubio-Valera M.

J Affect Disord. 2018 Jan 15;226:282-286. doi: 10.1016/j.jad.2017.09.057. Epub 2017 Oct 3.


Comparing watchful waiting with antidepressants for the management of subclinical depression symptoms to mild-moderate depression in primary care: a systematic review.

Iglesias-González M, Aznar-Lou I, Gil-Girbau M, Moreno-Peral P, Peñarrubia-María MT, Rubio-Valera M, Serrano-Blanco A.

Fam Pract. 2017 Nov 16;34(6):639-648. doi: 10.1093/fampra/cmx054.


Impact of initial medication non-adherence on use of healthcare services and sick leave: a longitudinal study in a large primary care cohort in Spain.

Aznar-Lou I, Fernández A, Gil-Girbau M, Sabés-Figuera R, Fajó-Pascual M, Peñarrubia-María MT, Serrano-Blanco A, Moreno-Peral P, Sánchez-Niubó A, March-Pujol M, Rubio-Valera M.

Br J Gen Pract. 2017 Sep;67(662):e614-e622. doi: 10.3399/bjgp17X692129. Epub 2017 Jul 31.


Cost-Utility of Group Acceptance and Commitment Therapy for Fibromyalgia Versus Recommended Drugs: An Economic Analysis Alongside a 6-Month Randomized Controlled Trial Conducted in Spain (EFFIGACT Study).

Luciano JV, D'Amico F, Feliu-Soler A, McCracken LM, Aguado J, Peñarrubia-María MT, Knapp M, Serrano-Blanco A, García-Campayo J.

J Pain. 2017 Jul;18(7):868-880. doi: 10.1016/j.jpain.2017.03.001. Epub 2017 Mar 23.


Initial medication non-adherence: prevalence and predictive factors in a cohort of 1.6 million primary care patients.

Aznar-Lou I, Fernández A, Gil-Girbau M, Fajó-Pascual M, Moreno-Peral P, Peñarrubia-María MT, Serrano-Blanco A, Sánchez-Niubó A, March-Pujol MA, Jové AM, Rubio-Valera M.

Br J Clin Pharmacol. 2017 Jun;83(6):1328-1340. doi: 10.1111/bcp.13215. Epub 2017 Feb 24.


Impact of IPDE-SQ personality disorders on the healthcare and societal costs of fibromyalgia patients: a cross-sectional study.

Gumà-Uriel L, Peñarrubia-María MT, Cerdà-Lafont M, Cunillera-Puertolas O, Almeda-Ortega J, Fernández-Vergel R, García-Campayo J, Luciano JV.

BMC Fam Pract. 2016 Jun 1;17:61. doi: 10.1186/s12875-016-0464-5.


Corrigendum to: "Evaluation of a pharmacist intervention on patients initiating pharmacological treatment for depression: A randomized controlled superiority trial" [Eur. Neuropsychopharmacol. 23(2013)1057-1066].

Rubio-Valera M, Pujol MM, Fernández A, Peñarrubia-María MT, Travé P, Del Hoyo YL, Serrano-Blanco A.

Eur Neuropsychopharmacol. 2016 Jun;26(6):1085. doi: 10.1016/j.euroneuro.2016.02.016. Epub 2016 May 5. No abstract available.


Cost-utility and biological underpinnings of Mindfulness-Based Stress Reduction (MBSR) versus a psychoeducational programme (FibroQoL) for fibromyalgia: a 12-month randomised controlled trial (EUDAIMON study).

Feliu-Soler A, Borràs X, Peñarrubia-María MT, Rozadilla-Sacanell A, D'Amico F, Moss-Morris R, Howard MA, Fayed N, Soriano-Mas C, Puebla-Guedea M, Serrano-Blanco A, Pérez-Aranda A, Tuccillo R, Luciano JV.

BMC Complement Altern Med. 2016 Feb 27;16:81. doi: 10.1186/s12906-016-1068-2.


Functional Status, Quality of Life, and Costs Associated With Fibromyalgia Subgroups: A Latent Profile Analysis.

Luciano JV, Forero CG, Cerdà-Lafont M, Peñarrubia-María MT, Fernández-Vergel R, Cuesta-Vargas AI, Ruíz JM, Rozadilla-Sacanell A, Sirvent-Alierta E, Santo-Panero P, García-Campayo J, Serrano-Blanco A, Pérez-Aranda A, Rubio-Valera M.

Clin J Pain. 2016 Oct;32(10):829-40. doi: 10.1097/AJP.0000000000000336.


[Impact of pharmaceutical intervention in preventing relapses in depression in Primary Care].

Rubio-Valera M, Peñarrubia-María MT, Fernández-Vergel R, Carvajal Tejadillo AC, Fernández Sánchez A, Aznar-Lou I, March-Pujol M, Serrano-Blanco A.

Aten Primaria. 2016 May;48(5):308-15. doi: 10.1016/j.aprim.2015.05.009. Epub 2015 Sep 26. Spanish.


Cost-effectiveness of active monitoring versus antidepressants for major depression in primary health care: a 12-month non-randomized controlled trial (INFAP study).

Rubio-Valera M, Beneitez I, Peñarrubia-María MT, Luciano JV, Mendive JM, McCrone P, Knapp M, Sabés-Figuera R, Kocyan K, García-Campayo J, Serrano-Blanco A.

BMC Psychiatry. 2015 Mar 31;15:63. doi: 10.1186/s12888-015-0448-3.


Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial.

Luciano JV, D'Amico F, Cerdà-Lafont M, Peñarrubia-María MT, Knapp M, Cuesta-Vargas AI, Serrano-Blanco A, García-Campayo J.

Arthritis Res Ther. 2014 Oct 1;16(5):451. doi: 10.1186/s13075-014-0451-y.


Evaluation of a pharmacist intervention on patients initiating pharmacological treatment for depression: a randomized controlled superiority trial.

Rubio-Valera M, March Pujol M, Fernández A, Peñarrubia-María MT, Travé P, López Del Hoyo Y, Serrano-Blanco A.

Eur Neuropsychopharmacol. 2013 Sep;23(9):1057-66. doi: 10.1016/j.euroneuro.2012.11.006. Epub 2012 Dec 6.


Clinical dimensions of fibromyalgia symptoms and development of a combined index of severity: the CODI index.

Cuesta-Vargas A, Luciano JV, Peñarrubia-María MT, García-Campayo J, Fernández-Vergel R, Arroyo-Morales M, Serrano-Blanco A; FibroQoL Study Group.

Qual Life Res. 2013 Feb;22(1):153-60. doi: 10.1007/s11136-012-0134-6. Epub 2012 Feb 26.


Effectiveness of a psychoeducational treatment program implemented in general practice for fibromyalgia patients: a randomized controlled trial.

Luciano JV, Martínez N, Peñarrubia-María MT, Fernández-Vergel R, García-Campayo J, Verduras C, Blanco ME, Jiménez M, Ruiz JM, López del Hoyo Y, Serrano-Blanco A; FibroQoL Study Group.

Clin J Pain. 2011 Jun;27(5):383-91. doi: 10.1097/AJP.0b013e31820b131c.


Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol.

Rubio-Valera M, Serrano-Blanco A, Travé P, Peñarrubia-María MT, Ruiz M, Pujol MM.

BMC Public Health. 2009 Aug 5;9:284. doi: 10.1186/1471-2458-9-284.


[Do we really follow the Mediterranean diet?].

Fernández-Vergel R, Peñarrubia-María MT, Rispau-Falgàs A, Espín-Martínez A, Gonzalo-Miguel L, Pavón-Rodríguez F.

Aten Primaria. 2006 Feb 28;37(3):148-53. Spanish.


Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine.

Serrano-Blanco A, Gabarron E, Garcia-Bayo I, Soler-Vila M, Caramés E, Peñarrubia-Maria MT, Pinto-Meza A, Haro JM; Depressió en Atenció Primària de Gavà Group (D. A. P. G. A.).

J Affect Disord. 2006 Apr;91(2-3):153-63. Epub 2006 Feb 3.


[How do we refer to mental health from primary care?].

Miranda Chueca I, Peñarrubia María MT, García Bayo I, Caramés Durán E, Soler Vila M, Serrano Blanco A.

Aten Primaria. 2003 Nov 30;32(9):524-30. Spanish.


[Non-cardiogenic acute pulmonary edema and recurrent leukopenia caused by hydrochlorothiazide].

Torné Cachot J, Peñarrubia María MT, Moner Coromina L.

Rev Clin Esp. 2001 Feb;201(2):107-8. Spanish. No abstract available.


Supplemental Content

Loading ...
Support Center